{
    "clinical_study": {
        "@rank": "144551", 
        "arm_group": [
            {
                "arm_group_label": "Treatment A", 
                "arm_group_type": "Placebo Comparator", 
                "description": "16 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 6 doses of 1 mg/kg"
            }, 
            {
                "arm_group_label": "Treatment B", 
                "arm_group_type": "Placebo Comparator", 
                "description": "16 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 3 doses of 3 mg/kg"
            }, 
            {
                "arm_group_label": "Treatment C", 
                "arm_group_type": "Placebo Comparator", 
                "description": "8 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 6 doses of 2 mg/kg"
            }, 
            {
                "arm_group_label": "Treatment D", 
                "arm_group_type": "Placebo Comparator", 
                "description": "8 subjects will be randomized to receive AMG 785 or placebo in a 3:1 ratio and will receive 3 doses of 2 mg/kg"
            }
        ], 
        "brief_summary": {
            "textblock": "This multicenter, randomized, double-blind, placebo-controlled, ascending multiple dose\n      study assesses the safety, tolerability, pharmacokinetics, and pharmacodynamics of\n      subcutaneous administration of 6 doses of 1 mg/kg AMG 785 once every 2 weeks or 3 doses of 3\n      mg/kg AMG 785 every 4 weeks in healthy men or postmenopausal women with low bone mass and 3\n      doses of 2 mg/kg AMG 785 every 4 weeks or 6 doses of 2 mg/kg AMG 785 every 2 weeks in\n      healthy postmenopausal women with low bone mass."
        }, 
        "brief_title": "A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785", 
        "completion_date": {
            "#text": "July 2009", 
            "@type": "Actual"
        }, 
        "condition": [
            "Postmenopausal", 
            "Osteopenia"
        ], 
        "condition_browse": {
            "mesh_term": "Bone Diseases, Metabolic"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy males and females between 45 to 80 years of age\n\n          -  Postmenopausal females\n\n          -  Low bone mineral density\n\n          -  25-hydroxyvitamin D \u2265 20 ng/mL\n\n          -  Weight \u2264 98 kg (216 lb) and/or height \u2264 196 cm (77 in)\n\n        Exclusion Criteria:\n\n          -  Osteoporosis\n\n          -  Subjects with fewer than 2 evaluable (by DXA) vertebrae; metal in hips bilaterally\n             that would not allow for at least one evaluable (by DXA) hip; metal in forearms\n             bilaterally that would not allow for at least one evaluable (by DXA) forearm\n\n          -  Previous exposure to AMG 785"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01825785", 
            "org_study_id": "20060221"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment A", 
                    "Treatment C"
                ], 
                "description": "Dose every 2 weeks", 
                "intervention_name": "Treatment Interval 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment B", 
                    "Treatment D"
                ], 
                "description": "Dose every 4 weeks", 
                "intervention_name": "Treatment Interval 2", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 3, 2013", 
        "link": {
            "description": "AmgenTrials clinical trials website", 
            "url": "http://www.amgentrials.com"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 785 in Healthy Men and Postmenopausal Women With Low Bone Mass", 
        "overall_official": {
            "affiliation": "Amgen", 
            "last_name": "MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2008", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Number (percent) of subjects reporting treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "169 days following initial investigational product administration"
            }, 
            {
                "measure": "Number (percent) of subjects who experienced clinically significant changes in safety laboratory tests, physical examinations, vital signs, or electrocardiograms", 
                "safety_issue": "Yes", 
                "time_frame": "169 days following initial investigational product administration"
            }, 
            {
                "measure": "Number (percent) of subjects who developed antibodies to AMG 785", 
                "safety_issue": "Yes", 
                "time_frame": "169 days following initial investigational product administration"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01825785"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum concentration-time curve (AUC), maximum observed concentration (Cmax), and time of maximum drug concentration (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "169 days following initial investigational product administration"
            }, 
            {
                "measure": "Bone mineral density as assessed by dual energy X-ray absorptiometry, serum procollagen type 1 N-terminal propeptide, osteocalcin, bone-specific alkaline phosphatase, serum CTX, intact Parathyroid Hormone, serum and ionized calcium, and sclerostin levels", 
                "safety_issue": "No", 
                "time_frame": "169 days following initial investigational product administration"
            }
        ], 
        "source": "Amgen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Amgen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}